September 14, 2022
Short-Acting β2-Agonists and Poor Clinical Outcomes in Asthma
The SABINA III study, which comprised 8351 participants from 24 countries, demonstrated that high SABA prescriptions led to poorer asthma control and higher rates of severe asthma exacerbations. Asthma is a prevalent health condition across the globe and the most common chronic condition during childhood. The emergence of inhaled corticosteroids has led to a significant...
Benralizumab in Eosinophilic Asthma and Nasal Polyposis
Benralizumab is effective in patients with nasal polyposis. Severe eosinophilic asthma also exhibits improved SNOT-22 and asthma outcomes with benralizumab. The combination of chronic rhinosinusitis (CRS) and nasal polyposis (NP) is a common chronic inflammatory disease. Patients may suffer from headaches and severe sinonasal symptoms that include increased nasal congestion, nasal polyp growth, loss or...
Neighborhood-Level Socioeconomic Disadvantage Linked to Poor MS Outcomes
Socioeconomic disadvantage may be a potential risk factor for poor clinical outcomes in patients with multiple sclerosis (MS). A retrospective analysis was conducted to assess this association and open the discussion for possible solutions. Patients with multiple sclerosis (MS) who are at a socioeconomic disadvantage may bear a high burden of disease and worse outcomes....
Insights Into the Prevalence and Treatment of MS
The prevalence of multiple sclerosis (MS) in minority populations is not well documented or understood. A retrospective cohort analysis evaluated the prevalence of MS with data gathered from a Florida database and provided insight into the prevalence and care of MS. Nearly one million people live with multiple sclerosis (MS) in the United States. However,...